How much is the chronic sialorrhea market worth, and how is it expected to expand?
The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, increase in population, increasing prevalence of neurological disorders, rising awareness and diagnosis, increase demand for non-invasive treatments.
The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing awareness about the treatment options, increasing the need for effective treatment options, growing healthcare expenditure, rising pediatric cases, and rising demand for oral gels and liquid. Major trends in the forecast period include telemedicine for remote monitoring, patient-centered care models, pharmacological innovations, integration of speech and occupational therapies, and development of long-acting pharmaceuticals.
Get Your Free Sample of The Global Chronic Sialorrhea Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp
Which industry factors have accelerated the chronic sialorrhea market’s expansion?
The increasing prevalence of neurodegenerative disorders is expected to propel the growth of the chronic sialorrhea market going forward. Neurodegenerative disorders refer to a group of diseases characterized by the progressive degeneration or death of nerve cells (neurons) in the brain and spinal cord. The rising neurodegenerative disorders are due to genetic factors and family history, environmental factors, better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication of neurodegenerative disorders like Parkinson’s disease and ALS, necessitating targeted treatments to prevent aspiration, enhance oral function, and improve patient comfort. For instance, in September 2023, according to Parkinson’s UK, a UK-based charitable company, approximately 153,000 individuals in the UK are currently living with Parkinson’s, and with an aging population, this number is projected to increase by 20% to an estimated 172,000 by 2030. Therefore, the increasing prevalence of neurodegenerative disorders will drive the growth of the chronic sialorrhea market.
What are the primary segments of the chronic sialorrhea market?
The chronic sialorrhea market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies
2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications
3) By Patient Population: Pediatric Patients, Adult Patients
4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings
Subsegments:
1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-adrenergic Agonists, Salivary Gland Modulators
2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections
3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)
4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip and Mouth Exercises, Artificial Salivary Glands
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report
Which firms are leading the chronic sialorrhea market?
Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.
Which market trends are set to define the future of the chronic sialorrhea market?
Major companies operating in the chronic sialorrhea market are focusing on developing innovative treatments, such as oral solutions, to improve patient compliance and provide non-invasive alternatives for managing chronic sialorrhea in children, enhancing safety and effectiveness while reducing side effects. An oral solution is a liquid medication formulated for oral administration, containing the active ingredient dissolved in a solvent, designed for easy ingestion. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. A key feature of this product is its liquid formulation, designed for ease of administration and accurate dosing, making it particularly beneficial for pediatric patients who struggle with solid medications. It offers a well-established safety and efficacy profile, helping to improve quality of life by reducing excessive drooling, which is a common challenge in neurodevelopmental conditions like cerebral palsy.
Which geographic trends are shaping the chronic sialorrhea market, and which region has the highest market share?
North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chronic Sialorrhea Market Report 2025 Offer?
The chronic sialorrhea market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chronic sialorrhea refers to the persistent excessive production or impaired control of saliva, often associated with neurological conditions such as Parkinson’s disease, cerebral palsy, or ALS. It is managed using pharmacological treatments, botulinum toxin injections, or surgical interventions to improve oral function, reduce complications, and enhance patients’ quality of life.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21149
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
